Lutetium therapy-induced carcinoid crisis: A case report and review of literature

Sanjay Kumar Yadav, Chandan Kumar Jha, Shrinivas Patil, Deepanksha Datta, Anjali Mishra, PK PradhanJournal of Cancer Research and Therapeutics 2020 16(8):206-208 Peptide receptor radionuclide therapy with 177lutetium (Lu)-labeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastatic neuroendocrine tumors. Some of these patients may present with carcinoid syndrome and it is known that rarely carcinoid crisis can be precipitated by surgical or other interventions in these patients. However, there are anecdotal reports of carcinoid crisis after Lu-labeled peptide therapy. We are reporting our experience of successful management of one such case of carcinoid crisis which was precipitated by Lu therapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research